The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Princeton: Bristol Myers Squibb and Bain Capital have announced the formation of a new independent biopharmaceutical company, ...

Bain Capital and Bristol Myers Squibb have formed a new biopharmaceutical company focused on developing new therapies for autoimmune diseases. The newly formed company launches with a $300 million ...

Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, & Head of Development starting Aug 2025.

The companies’ new effort would bypass traditional middlemen to cut the drug’s monthly cost from a list price of around $606 ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.